[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"impulse-control-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:impulse-control-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,67,91,136,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100631800","efficacy-of-a-prediction-model-based-algorithm-to-prevent-drug-induced-impulse-control-disorders-in-parkinsons-disease-100631800",false,"NCT07505394","Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease","PREVENT-ICD","Inclusion Criteria:\n\n* Male and female ≥ 18 years old\n* Diagnosis of PD according to the 2015 Movement Disorders Society criteria (Postuma et al., Mov Disord. 2015), with bradykinesia AND at least ONE of the following: muscular rigidity, or resting tremor; with no other suspected cause of parkinsonism\n* Disease duration below 6 years included\n* No ongoing clinically significant (Mild or above) ICDRBs (any ASBPD part IV subscores in any of the items 3 to 5 and 7 to 10 each \\\u003C2)\n* Patients currently treated with DA for at least 2 months and without current planned or known reason for stopping DA over the next 3 years\n\nExclusion Criteria:\n\n* Atypical or secondary parkinsonism such as supranuclear palsy, multisystem atrophy or drug-induced parkinsonism, etc...\n\n  * Patients with a cognitive or psychiatric disorder preventing patient's participation as per investigator's judgement\n  * Not willing to participate to the Clinical Investigation or to sign the consent\n  * Pregnant or lactating woman, or WOCBP tested positive in \\\u003Cserum or urine\\> pregnancy test\n  * Participation in investigational drug trials within 30 days prior to screening or within 5 half-life of investigational product whatever the longest\n  * Participant not affiliated or beneficiary of a French social security system","ALL","18 Years",{"count":19,"type":20},528,"ESTIMATED","INTERVENTIONAL",[23],"NA","Impulse control disorders and related behaviors (ICDRBs) are characterized by pathological gambling, compulsive shopping or eating, and hypersexuality, but other related behaviors have been described, e.g. hobbyism, and punding. ICDRBs are frequent in Parkinson's Disease (PD), affecting up to 50% of the patients after 5 years with major medical, social, and legal impact, with life changing consequences for patients and caregivers. The main risk factor is dopaminergic therapy, particularly the cumulative dose of dopamine agonists (DA). On the other hand, the dopaminergic therapy is necessary to control motor symptoms, and DA have demonstrated efficacy in delaying motor complications occurring in PD. Ideally, dopaminergic therapy would have to be adjusted to the individual risk of developing ICRDBs to maximize the benefit\u002Frisk ratio of each drug. However, despite several clinical risk factors associated with the risk of ICDRBs (in addition to the dopaminergic therapy), it is still not possible to predict their risk at the individual level, and not every patient treated with dopaminergic medications will develop ICDRBs. A machine learning algorithm to predict ICDRBs, based on clinical data, validated by cross-validation on independent replication cohorts has been developed. The PREVENT-ICD study proposes to test the efficacy of a new application, ICD-Shield, based on an algorithm to predict and prevent ICDs,in a multicenter randomized controlled trial to prevent ICDRBs in PD patients by proposing to the clinician treatment adjustment according to the risk predicted by the algorithm, as compared to the standard of care (SoC)",[26,27],"Parkinson Disease","Impulse Control Disorder",[29,30,31],"Agonists, Dopamine","Impulse Control Disorders","ICD SHIELD app","NOT_YET_RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":20},"2026-07-01",{"date":40,"type":20},"2031-06-01",{"name":42,"class":43},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100534364","rtms-over-the-dorsolateral-prefrontal-cortex-for-the-treatment-of-impulse-control-disorders-in-parkinsons-disease-100534364","NCT06237868","rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease","The Effects of High-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Control Disorders in Parkinson's Disease Patients on Dopamine Replacement Therapy.","Inclusion Criteria:\n\n* Clinician-confirmed diagnosis of PD\n* Ability to provide informed consent, written and verbal\n* Clinician-diagnosed impulse control disorder or impulse control behaviors including punding\u002Fhobbyism and dopamine dysregulation syndrome\n* A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower\n* A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher\n* On dopamine-replacement therapy\n\nExclusion Criteria:\n\n* History of seizures or epilepsy\n* History of brain lesions (such as multiple sclerosis, tumor) reported\n* History of vascular issues in the brain, such as stroke\n* History of a moderate to severe traumatic brain injury\n* Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher).\n* Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005)\n* Having had TMS done in the recent past (within a year)\n* Pregnancy assessed in female patients\n* Intracranial metallic objects (except for dental fillings)\n* Current use of substances or medications known to significantly reduce seizure threshold.",{"count":52,"type":20},20,[23],"This study's objective is to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC) of patients with Parkinson's Disease (PD) who experience impulse control disorders (ICDs) on impulse control symptoms and cognitive behaviors linked to ICDs: reinforcement learning and delay-discounting. This is a randomized sham-controlled cross-over trial. All patients will undergo a session of active rTMS and a session of sham rTMS, with the order of sessions randomized across participants. Following recruitment and eligibility screening, the eligible participants will undergo two sessions of rTMS (active and sham), immediately followed by neurocognitive tasks and questionnaires, no more than 1-2 weeks apart. Each session will have a duration of approximately 1-1.5 hours.",[27,26],"RECRUITING","2026-04-16",{"date":59,"type":36},"2026-04-20",{"date":61,"type":36},"2024-05-01",{"date":63,"type":20},"2027-05",{"name":65,"class":43},"West Virginia University",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":66},"100565239","phase-1-feasibility-of-accelerated-personalized-rtms-as-an-adjuvant-for-impulse-control-disorders-a-pilot-study-100565239","NCT06639594","Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study","RAPID","Inclusion Criteria:\n\n1. Age 21 to 60\n2. BMI\\>30 (confirmed at in person visit)\n3. Able to follow verbal and written instructions in English and complete all aspects of the study.\n4. Have an address and telephone number where they may be reached.\n5. Subjects must report current stable residence. Stable residence is a domicile in which an individual can operate as if it were their own homestead and does not include shelters, halfway houses, treatment centers, or group homes.\n6. Meet safety criteria for EEG and rTMS.\n7. Willing and able to independently remove any metal from the neck and above for rTMS procedures (e.g., jewelry, retainer)\n8. Provides written informed consent and agree to all assessments and study procedures.\n9. Agrees to complete telehealth (live audio-video conference and phone) and in-person visits and to be contacted via text.\n\nExclusion Criteria\n\n1. rTMS exposure for treatment or research purposes in the last 6 months.\n2. History of seizure, epilepsy, syncope, fainting episode, or head trauma resulting in loss of consciousness.\n3. Presence or history of neurological disorders (migraine, stroke, Alzheimer's Disease and other Dementias, Parkinson's Disease, Multiple Sclerosis, Traumatic Brain Injury (TBI), increased intracranial pressure).\n4. History of brain surgery, implanted electronic device, metal in the head.\n5. Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps or sensors, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes)\n6. History of or currently under medical care for myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke, or transient ischemic attack.\n7. Reported history of vision problems that are not treated.\n8. Has a hairstyle not compatible with the EEG net that is required to be worn on the scalp during the experimental procedure.\n9. Reports current diagnosis or history of type I diabetes.\n10. Currently using insulin.\n11. Have undergone bariatric surgery.\n12. Currently being enrolled in a weight loss program\n13. Takes any prescription or over the counter medications or supplements to control weight and\u002For appetite.\n14. Self-report a history of or current diagnosis of a mental health condition.\n15. Reports insomnia (\\\u003C4 hours sleep per night, in 3 or more nights per week in the last 3 months)\n16. Reports (\\\u003C4 hours of sleep) the day of the visit.\n17. Reports using marijuana on a daily basis.\n18. Reports having used any other illicit drugs (other than marijuana) or prescription medications for non-medical reasons in the last 12 months.\n19. Currently receiving treatment for substance use disorder (e.g., alcohol, opioids, cocaine, marijuana, or stimulants).\n20. Females who report averaging more than 7 alcoholic drinks, or males who report averaging more than 14 alcoholic drinks in a single week in the last 30 days.\n21. Current use of certain medications (last 3 months):\n\n    * Investigational drugs.\n    * Drugs of anti or pro-convulsive action. Medications with psychotropic effects (e.g., antidepressants, antipsychotics).\n    * Medications known to increase risk of seizure taken within 1 week of enrollment.\n    * Smoking cessation medication (e.g., Zyban, Wellbutrin, Wellbutrin SR, Chantix).\n22. Being pregnant or lactating\n23. Reported allergies to chocolate or any ingredient in the M\\&M candies.\n24. Noise-induced hearing loss or tinnitus.\n25. Currently participating in any other research study.\n26. Any otherwise not specified medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and\u002For Study Physician\n27. Subjects considered by the investigator as unsuitable for the study for reasons not otherwise stated.","21 Years","60 Years",{"count":77,"type":20},30,[79],"PHASE1","To learn if accelerated rTMS (repetitive transcranial magnetic stimulation) can be used as a possible therapy for excessive eating.",[27],"2026-03-19",{"date":84,"type":36},"2026-03-23",{"date":86,"type":36},"2024-11-21",{"date":88,"type":20},"2027-11-03",{"name":90,"class":43},"M.D. Anderson Cancer Center",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":118,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":66},"100493968","neurostimulation-versus-therapy-for-problems-with-emotions-100493968","NCT05712057","Neurostimulation Versus Therapy for Problems With Emotions","Neurostimulation Enhanced Cognitive Restructuring for Transdiagnostic Emotional Dysregulation: A Component Analysis","Inclusion Criteria:\n\n* age 18 to 55\n* elevated overall score on Difficulties with Emotion Regulation Scale (DERS total score \\>=90)\n* has been in the same type of psychotherapy (including none) for the last 4 weeks\u002F1mo (\\*except for current CBT) and is willing to stay on the same regimen throughout the study.\n* low self-reported use of cognitive restructuring (ERQ restructuring subscale average score \\\u003C 4.7)\n* meets criteria for at least one mood (including Bipolar II w\u002Fo current hypomania), anxiety, stressor, OCD, Impulse Control, ADHD, or eating DSM-5 disorder (except exclusionary diagnoses such as severe anorexia). Note: Both current or partial remission of the disorder will be ok for inclusion into the study.\n* verbal agreement to maintain dose of prescribed psychotropic medication (if any) constant throughout the study, provided they are stable on it for the past 4 weeks (except exclusion medication and except if there is a medical emergency requiring changes in medication).\n* Naïve to rTMS\n\nExclusion Criteria:\n\n* current hypomania (Note: Bipolar II w\u002Fo current hypomanic episode is ok for inclusion)\n* meets diagnostic criteria for current or history of psychotic disorder, or psychotic features,\n* meets diagnostic criteria for Bipolar I disorder\n* meets diagnostic criteria on SCID5 for current alcohol or substance use disorder (moderate and high severity) or meets past history of severe alcohol use disorder\n* unable to read, blind, or deaf, or unwilling to give consent\n* non-English speaker,\n* verbal IQ \\\u003C 90 on the North American Adult Reading Test (NART).\n* current uncontrolled anorexia or other condition requiring hospitalization\n* high risk for suicide defined as either having attempted suicide in past 6 months or reporting current suicidal ideation that includes a method, plan, or intent to die\n* current serious medical illness, including current severe migraine headaches\n* started\u002Fchanged psychotropic medications in the prior 4 weeks, or plans to change medication during the study\n* history of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesions that are contraindications for TMS, devices that may be affected by TMS (pacemaker, medication pump, cochlear implant, implanted brain stimulator), have left elbow\u002Fhand\u002Fwrist tendonitis\n* conditions associated with increased intracranial pressure, space occupying brain lesion (considered significant and unsafe for TMS by the study MD), transient ischemic attack, cerebral aneurysm, dementia, Parkinson's or Huntington's disease, multiple sclerosis\n* Wellbutrin \\>300mg per day or on daily stimulant\u002FADHD medications above the recommended FDA daily recommendations\n* use of investigational drug or devices within 4 weeks of screening\n* cochlear implants\n* Pregnancy\n* metal in body that would exclude them from the MRI scan; severe claustrophobia\n* is a prisoner or in police custody at time of screening, or has pending court case jeopardizing the participation in the study\n* has had TMS in their lifetime\n* has had CBT in the past 4 weeks or plans to start therapy during the study\n* weighs over 300 pounds (could not fit in MRI scanner)","55 Years",{"count":100,"type":20},240,[23],"The primary goal of this clinical trial is to evaluate the unique neural and behavioral effects of a one-session training combining emotion regulation skills training, with excitatory repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC). The secondary aim is to identify key changes in the emotion regulation neural network following the combined intervention versus each of the components alone. The third aim is to explore personalized biomarkers for response to emotion regulation training.\n\nParticipants will undergo brain imaging while engaging in an emotional regulation task. Participants will be randomly assigned to learn one of two emotion regulation skills. Participants will be reminded of recent stressors and will undergo different types of neurostimulation, targeted using fMRI (functional MRI) results. Participants who may practice their emotion regulation skills during neurostimulation in a one-time session. Following this training, participants will undergo another fMRI and an exit interview to assess for immediate neural and behavioral changes. Measures of emotion regulation will be assessed at a one week and a one month follow up visit.",[104,105,106,107,108,27,109,110,111,112,113,114,115,116,117],"Emotion Regulation","Mood Disorders","Stress Disorder","Anxiety Disorders","OCD","Eating Disorders","Emotional Dysfunction","Emotional Instability","Emotional Distress","Emotional Maladjustment","Emotional Impulsivity","Obsessive-Compulsive Disorder","Emotion Dysregulation","Borderline Personality Disorder",[116,119,120,121,122,123,124,125,126],"Distress Intolerance","Neuromodulation","Neurostimulation","TMS","cognitive restructuring","regulation skills","neuroimaging","Emotion regulation","2026-03-02",{"date":129,"type":36},"2026-03-04",{"date":131,"type":36},"2023-05-15",{"date":133,"type":20},"2027-12-01",{"name":135,"class":43},"Duke University",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100559268","stimpulsecontrol-ancillary-speech-study-100559268","NCT06561919","STIMPulseControl Ancillary Speech Study","Inclusion Criteria:\n\nPlease refer to main study (STIMPulseControl KKS-313)\n\nExclusion Criteria:\n\nPlease refer to main study (STIMPulseControl KKS-313)","70 Years",{"count":144,"type":20},60,[23],"Speech assessment is a substudy to the STIMPulseControl study (hereinafter referred to as the main study), where audio recordings of patients voices will be recorded as part of a speech analysis in the main study, for this optional ancillary study.",[26,27],[149],"Speech","2025-12-01",{"date":152,"type":36},"2025-12-02",{"date":154,"type":36},"2024-09-05",{"date":156,"type":20},"2028-07-15",{"name":158,"class":43},"Steffen Paschen",12,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":66},"100553430","frontosubthalamic-networks-in-parkinsons-disease-100553430","NCT06485986","Frontosubthalamic Networks in Parkinson's Disease.","Frontosubthalamic Network Dynamics and Their Modulation During Impulse Control and Decision Making in Parkinson's Disease","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 18 years or above.\n* Diagnosed with Parkinson's disease who have required implanted STN electrodes for DBS in addition to their dopamine replacement therapy.\n* Diagnosed with or without (control group) impulse control disorders since the diagnosis of Parkinson's Disease.\n* Participant willing and able to sit in the MEG scanner and follow instructions.\n* Participant willing and able to delay their morning dose of dopamine replacement therapy for up to four hours (180 minutes experimental time + journey time).\n\nExclusion Criteria:\n\n* Patients with extreme language barrier that cannot understand the purpose or instructions of the study despite the use of an interpreter.\n* Other implanted medical devices that may cause artefacts during MEG recordings.\n* Participants with a history of co-morbid neurological disorders.\n* Participant enrolled onto another clinical trial related to a neurological disorder (including Parkinson's disease) that may interfere with the results of this study.\n* Participants who are unable to sit still in a MEG scanner for the duration of this experiment e.g. patients with chronic pain or osteoarthritis. This will be assessed with their primary clinician",{"count":52,"type":20},[23],"The goal of this experimental study with is to understand the underlying mechanisms behind the increase in impulsivity seen in some patients that undergo deep brain stimulation of the subthalamic nucleus for Parkinson's Disease. The main questions it aims to answer are:\n\nWhat are the distributed network effects of deep brain stimulation to the subthalamic nucleus? How does this correlate with increased impulsivity? Can alternative stimulation settings be used to minimize these?\n\nParticipants will complete decision-making tasks whilst their deep brain stimulation devices are turned on and off with simultaneous magnetoencephalography recordings (a type of non-invasive brain scan that measures brain activity in real-time)",[26,27],[172],"Deep brain stimulation","2025-03-27",{"date":175,"type":36},"2025-04-02",{"date":177,"type":36},"2024-06-01",{"date":179,"type":20},"2026-08-31",{"name":181,"class":43},"University of Oxford"]